Overall dermatologicals has not been strongly affected by the arrival of COVID-19, though deceleration or decline is occurring in most categories. Certain usually stable areas have taken a noticeable hit.
Demand for vaginal antifungals is beginning to stabilise as many Finns suffer from yeast infections and are changing the way they address the issue. Rather than visiting a doctor, they are showing an increasing preference for self-care in this matter, which they can address in the privacy of their own homes.
Dermatologicals continues to be led by large players Bayer Oy, Janssen-Cilag Oy and Orion Oyj in 2020, with very little movement in their value shares being observed as consumers are buying dermatologicals less often and at the same time shopping around less, causing lesser-known players and their brands to lose share. Also, Bayer, Janssen-Cilag and Orion have the size to adapt to the ongoing migration to e-commerce among social-distancing consumers, offering a wide product selection online and convenient delivery services.
Sales are likely to bounce back in 2021 if no new waves of COVID-19 are experienced in Finland that could lead to a further lockdown and therefore less demand for dermatologicals. The lingering threat of COVID-19 is likely to keep reducing visits to the doctor in cases where the consumer feels that self-care is a viable alternative, eg for vaginal antifungals.
Cold sore treatments is set to return to value sales growth in 2021 for the first time in several years, and ongoing rises are predicted throughout the forecast period. Higher value growth is being supported by innovative products such as Zoviduo from GSK Consumer Healthcare, which has the dual effect of stopping the growth of the herpes virus in addition to reducing inflammation and redness.
The consolidated competitive landscape of vaginal antifungals is likely to experience some disruption over the forecast period, with dynamic player Ratiopharm Oy entering the category towards the end of the review period. Ratiopharm offers a series of products (Vagibalance ratiopharm and Vagimoist ratiopharm), targeting women suffering from yeast infections or dryness due to a number of factors.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
Understand the latest market trends and future growth opportunities for the Medicated Skin Care industry in Finland with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Medicated Skin Care industry in Finland, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
This report originates from Passport, our Medicated Skin Care research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Home Page